SCHEMBL1978256

SCHEMBL1978256

CCCCOC(=O)c1nc(-c2ccccc2)c2cc(-c3ccccc3)sc2c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
POLB P06746 1/20 0.48
EGFR P00533 1/20 0.43
CNR2 P34972 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.41
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
GAA P10253 2/20 0.40
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 3/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX15 P16050 1/20 0.39
ESR1 P03372 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971890 0.93 MAPT (0.47) MAPTPOLBEGFRCNR2L3MBTL1
SCHEMBL1975813 0.85 POLB (0.42) MAPTPOLBCNR2L3MBTL1TSHR
SCHEMBL1976686 0.84 SCN9A (0.42) MAPTPOLBCNR2L3MBTL1TSHR
SCHEMBL1975055 0.83 EGLN1 (0.41) MAPTPOLBCNR2L3MBTL1TSHR
SCHEMBL1973776 0.83 EGFR (0.45) EGFRCNR2L3MBTL1TSHRTDP1
SCHEMBL1972719 0.81 TRPM8 (0.41) MAPTPOLBL3MBTL1TSHRTDP1
SCHEMBL1975336 0.81 KDM4E (0.43) MAPTPOLBL3MBTL1TSHRGAA
SCHEMBL1974153 0.81 POLB (0.42) MAPTPOLBCNR2L3MBTL1TSHR
SCHEMBL1973276 0.81 MAPT (0.43) MAPTPOLBL3MBTL1ALDH1A1HPGD
SCHEMBL1973105 0.80 SCN9A (0.42) MAPTPOLBCNR2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 MAPT 3256/4885POLB 2680/4885EGFR 4595/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 MAPT 3256/4885POLB 2680/4885EGFR 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.